Evoke Pharma, Inc. Stock

Equities

EVOK

US30049G2030

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-04-19 pm EDT 5-day change 1st Jan Change
0.4685 USD -2.15% Intraday chart for Evoke Pharma, Inc. -8.14% -55.39%
Sales 2024 * 14.08M Sales 2025 * 21.9M Capitalization 3.97M
Net income 2024 * -3M Net income 2025 * 1M EV / Sales 2024 * 0.28 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.18 x
P/E ratio 2024 *
-2.04 x
P/E ratio 2025 *
15.6 x
Employees 4
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.15%
1 week-8.14%
Current month-23.20%
1 month-23.07%
3 months-39.16%
6 months-63.40%
Current year-55.39%
More quotes
1 week
0.42
Extreme 0.4159
0.57
1 month
0.42
Extreme 0.4159
0.68
Current year
0.42
Extreme 0.4159
1.15
1 year
0.42
Extreme 0.4159
2.40
3 years
0.42
Extreme 0.4159
21.72
5 years
0.42
Extreme 0.4159
72.75
10 years
0.42
Extreme 0.4159
133.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 06-12-31
Chief Tech/Sci/R&D Officer 76 13-11-30
Members of the board TitleAgeSince
Founder 75 06-12-31
Director/Board Member 71 07-05-31
Director/Board Member 52 07-05-31
More insiders
Date Price Change Volume
24-04-19 0.4685 -2.15% 1,943
24-04-18 0.4788 -12.79% 21,941
24-04-17 0.549 +16.81% 20,068
24-04-16 0.47 -1.09% 25,436
24-04-15 0.4752 -6.82% 26,133

Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT

More quotes
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.4685 USD
Average target price
7 USD
Spread / Average Target
+1,394.13%
Consensus